59.97
price down icon0.18%   -0.11
after-market After Hours: 59.97
loading
Halozyme Therapeutics Inc stock is traded at $59.97, with a volume of 2.47M. It is down -0.18% in the last 24 hours and up +15.28% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$60.08
Open:
$59.9
24h Volume:
2.47M
Relative Volume:
0.99
Market Cap:
$7.39B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
19.86
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+2.04%
1M Performance:
+15.28%
6M Performance:
+5.88%
1Y Performance:
+8.52%
1-Day Range:
Value
$59.86
$61.75
1-Week Range:
Value
$57.67
$61.75
52-Week Range:
Value
$42.01
$70.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
Name
Halozyme Therapeutics Inc
Name
Phone
(858) 794-8889
Name
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
Employee
350
Name
Twitter
@halozymeinc
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
HALO's Discussions on Twitter

Compare HALO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HALO
Halozyme Therapeutics Inc
59.97 7.40B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Resumed Goldman Neutral
May-14-25 Downgrade Morgan Stanley Overweight → Equal-Weight
May-13-25 Downgrade Leerink Partners Market Perform → Underperform
Oct-07-24 Downgrade Wells Fargo Overweight → Equal Weight
Sep-19-24 Downgrade JP Morgan Overweight → Neutral
Jun-07-24 Downgrade Piper Sandler Overweight → Neutral
Feb-29-24 Initiated TD Cowen Outperform
Jul-24-23 Downgrade Goldman Buy → Neutral
Jul-24-23 Initiated H.C. Wainwright Buy
May-10-23 Upgrade Piper Sandler Neutral → Overweight
Mar-27-23 Resumed Berenberg Buy
Mar-16-23 Downgrade SVB Securities Outperform → Market Perform
Dec-21-22 Resumed Morgan Stanley Overweight
Nov-28-22 Initiated Wells Fargo Overweight
Sep-09-22 Initiated Morgan Stanley Overweight
May-23-22 Initiated SVB Leerink Outperform
Jun-14-21 Initiated Evercore ISI Outperform
May-17-21 Initiated SVB Leerink Outperform
May-11-21 Downgrade Piper Sandler Overweight → Neutral
Jan-21-21 Reiterated The Benchmark Company Buy
Dec-17-20 Initiated Berenberg Buy
Sep-14-20 Resumed JP Morgan Overweight
Jul-01-20 Initiated The Benchmark Company Buy
Feb-05-20 Upgrade Piper Sandler Neutral → Overweight
Jan-09-20 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-08-20 Initiated Goldman Buy
Nov-05-19 Upgrade Barclays Underweight → Equal Weight
Oct-19-18 Resumed Piper Jaffray Neutral
May-11-18 Downgrade Barclays Equal Weight → Underweight
Jan-24-18 Initiated Goldman Neutral
Oct-16-17 Reiterated Piper Jaffray Overweight
Jan-06-17 Downgrade Citigroup Buy → Neutral
Nov-03-16 Initiated Deutsche Bank Buy
Dec-04-15 Initiated Wells Fargo Outperform
Nov-18-15 Initiated Citigroup Buy
Sep-22-15 Initiated Barclays Overweight
Jun-22-15 Reiterated JP Morgan Overweight
Mar-03-15 Reiterated UBS Buy
Feb-18-15 Reiterated MLV & Co Buy
Jan-08-15 Reiterated MLV & Co Buy
View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

pulisher
Jul 30, 2025

What catalysts could drive Halozyme Therapeutics Inc. stock higher in 2025Stock Strategy Signals For Consistent Profits - jammulinksnews.com

Jul 30, 2025
pulisher
Jul 30, 2025

Halozyme Therapeutics Insider Lowered Holding By 38% During Last Year - 富途牛牛

Jul 30, 2025
pulisher
Jul 30, 2025

Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT - MSN

Jul 30, 2025
pulisher
Jul 29, 2025

How Halozyme Therapeutics Inc. stock performs during market volatilitySmart Money Tracking Signal Generator Activated - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Short Interest Drops in Halozyme Therapeutics Inc. After RallyOversold Recovery Opportunity Stocks Attract Buyers - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

Halozyme Therapeutics Inc. Outperforms Peers on Volume MetricsPrice Action Based Buy Opportunity List Published - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Why Halozyme Therapeutics Inc. stock attracts strong analyst attentionProfit Target Stock Opportunity Monitor Activated - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

How Resilient Is Halozyme Therapeutics Inc. Stock During Economic DownturnsMarket Entry and Exit Point Tips From Traders - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Does Halozyme Therapeutics Inc. stock perform well during market downturnsBuild a strong portfolio for growth and safety - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What is Halozyme Therapeutics Inc. company’s growth strategyOutstanding capital returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-28 01:53:45 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Halozyme’s Promising Cancer Study: A Potential Game-Changer in Oncology - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Should I buy Halozyme Therapeutics Inc. stock before earningsRecord-setting profit potential - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What risks could impact Halozyme Therapeutics Inc. stock performanceConsistently superior profits - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Halozyme Therapeutics Inc. stockExceptional return forecasts - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

38% Of This Halozyme Therapeutics Insider's Holdings Were Sold - simplywall.st

Jul 24, 2025
pulisher
Jul 24, 2025

Is Halozyme Therapeutics Inc. stock overhyped or has real potentialBreakout profit opportunities - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Halozyme to Report Second Quarter 2025 Financial and Operating Results - Eastern Progress

Jul 24, 2025
pulisher
Jul 23, 2025

BlackRock, Inc. Adjusts Holdings in Halozyme Therapeutics Inc. - GuruFocus

Jul 23, 2025
pulisher
Jul 23, 2025

Halozyme Therapeutics Inc. Stock Analysis and ForecastExceptional profit margins - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Halozyme Therapeutics Says Myeloma Drug With Enhanze Delivery Technology Gets EU Approval - 富途牛牛

Jul 23, 2025
pulisher
Jul 23, 2025

Is Halozyme Therapeutics Inc. a good long term investmentFree Risk Assessment Services - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

J&J Darzalex injectable cleared in EU for smouldering MM (JNJ) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

Halozyme says EU approves new indication for Janssen’s Darzalex Faspro - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma - WV News

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Halozyme Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Halozyme to Present Q2 2025 Financial Results After Market Close on August 5 - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Halozyme Stock Maintains Hold Rating Amid CMS Pricing Uncertainty and Regulatory Concerns. - AInvest

Jul 22, 2025

Halozyme Therapeutics Inc Stock (HALO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):